Exploring Negative Symptoms of Schizophrenia: Where Do We Stand?

A special issue of Brain Sciences (ISSN 2076-3425). This special issue belongs to the section "Psychiatric Diseases".

Deadline for manuscript submissions: 25 November 2024 | Viewed by 676

Special Issue Editors


E-Mail Website
Guest Editor
Psychiatry Department, University of Caen Normandy, 14000 Caen, France
Interests: schizophrenia; negative symptoms; physical activity; antipsychotics; brain imaging; neurostimulation

E-Mail Website
Guest Editor
Department of Adult Psychiatry, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
Interests: first episode psychosis; negative symptoms; treatment response; treatment resistance; suicidal behaviors; illness trajectories; prediction

E-Mail
Guest Editor
Department of Acute Psychiatry, Oslo University Hospital, Oslo, Norway
Interests: psychosis; negative symptoms; understanding reduced motivation in psychotic disorders; clinical trials, user involvement; global mental health

Special Issue Information

Dear Colleagues,

Negative symptoms are prevalent among many individuals diagnosed with schizophrenia, and these significantly impact their social functioning and overall quality of life. Despite their significant impact, negative symptoms have often been overshadowed in diagnostic criteria, treatment approaches, and research pertaining to schizophrenia, especially when compared to positive symptoms. Additionally, there remains a lack of clarity in clinical practice regarding the definition and differentiation between primary and secondary negative symptoms. Nevertheless, recognizing secondary negative symptoms is crucial, as this can enable tailored treatment interventions, especially considering the fact that these symptoms can stem from various factors such as positive symptoms, substance abuse, medication side effects, or depressive episodes.

The objective of this Special Issue, therefore, is to offer fresh insights into negative symptoms by presenting clinical tools, brain imaging studies, physiological data, and innovative treatment modalities.

Controlled trials involving medications targeting neurotransmitter systems other than dopamine, or exploring adjunctive therapies alongside antipsychotics, such as neurostimulation, cognitive remediation, physical activity, or social rehabilitation, are anticipated. Furthermore, research aimed at enhancing our understanding of the pathophysiology underlying negative symptoms is encouraged, and original research, meta-analyses, and reviews may be accepted.

Prof. Dr. Sonia Dollfus
Prof. Dr. Ingrid Melle
Dr. Ann Faerden
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Brain Sciences is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • schizophrenia
  • negative symptoms
  • brain imaging
  • pathophysiology
  • scales
  • cognitive remediation
  • physical activity
  • neurostimulation
  • social rehabilitation
  • neurotransmitter
  • drugs
  • quality of life
  • treatment
  • antipsychotics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 1109 KiB  
Article
Contrasting Effects of Oxytocin on MK801-Induced Social and Non-Social Behavior Impairment and Hyperactivity in a Genetic Rat Model of Schizophrenia-Linked Features
by Daniel Sampedro-Viana, Toni Cañete, Paula Ancil-Gascón, Sonia Cisci, Adolf Tobeña and Alberto Fernández-Teruel
Brain Sci. 2024, 14(9), 920; https://doi.org/10.3390/brainsci14090920 - 13 Sep 2024
Viewed by 502
Abstract
Social withdrawal in rodents is a measure of asociality, an important negative symptom of schizophrenia. The Roman high- (RHA) and low-avoidance (RLA) rat strains have been reported to exhibit differential profiles in schizophrenia-relevant behavioral phenotypes. This investigation was focused on the study of [...] Read more.
Social withdrawal in rodents is a measure of asociality, an important negative symptom of schizophrenia. The Roman high- (RHA) and low-avoidance (RLA) rat strains have been reported to exhibit differential profiles in schizophrenia-relevant behavioral phenotypes. This investigation was focused on the study of social and non-social behavior of these two rat strains following acute administration of dizocilpine (MK801, an NMDA receptor antagonist), a pharmacological model of schizophrenia-like features used to produce asociality and hyperactivity. Also, since oxytocin (OXT) has been proposed as a natural antipsychotic and a potential adjunctive therapy for social deficits in schizophrenia, we have evaluated the effects of OXT administration and its ability to reverse the MK801-impairing effects on social and non-social behavior and MK801-induced hyperactivity. MK801 administration produced hyperlocomotion and a decrease in social and non-social behavior in both rat strains, but these drug effects were clearly more marked in RHA rats. OXT (0.04 mg/kg and 0.2 mg/kg) attenuated MK801-induced hyperlocomotion in both rat strains, although this effect was more marked in RHA rats. The MK801-decreasing effect on exploration of the “social hole” was moderately but significantly attenuated only in RLA rats. This study is the first to demonstrate the differential effects of OXT on MK801-induced impairments in the two Roman rat strains, providing some support for the potential therapeutic effects of OXT against schizophrenia-like symptoms, including both a positive-like symptom (i.e., MK801-induced hyperlocomotion) and a negative-like symptom (i.e., MK801 decrease in social behavior), while highlighting the importance of the genetic background (i.e., the rat strain) in influencing the effects of both MK801 and oxytocin. Full article
(This article belongs to the Special Issue Exploring Negative Symptoms of Schizophrenia: Where Do We Stand?)
Show Figures

Figure 1

Back to TopTop